Extensive background and on-study uptake of TTR stabilizers likely diluted the observable marginal effect of a TTR-silencing agent, complicating attribution of benefit in the intent-to-treat primary ...
In today's Pharmaceutical Executive Daily, FDA approves Ennumo, a pharma roundup covers Chemomab Therapeutics' merger with AI ...
Sanofi Chief Digital Officer Emmanuel Frenehard on scaling AI across a Big Pharma global enterprise and why a strategy of ...
FDA cleared Ennumo as a Neulasta biosimilar for febrile neutropenia prophylaxis in non-myeloid malignancy patients receiving myelosuppressive chemotherapy, including pediatric populations from ...
Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
Transaction terms include $85-per-share all-cash consideration (~$10B enterprise value) and an anticipated Q3 2026 close, contingent on customary conditions. Portfolio fit emphasizes serious, ...
Bansi Nagji, CEO of PANTHERx Rare, explores how innovation is increasingly directed toward rare and orphan diseases, driven ...
Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
Resilient field models emphasize continuous territory coverage via agile deployment, blending scalable virtual reach with ...
Novartis filed New Jersey notices for 322 East Hanover layoffs starting October 2, after earlier filings for 76 cuts at the same site. Disclosures to date do not specify impacted functions, job ...
A joint framework is being built to convert Israeli academic target biology into viable small-molecule programs by integrating AI-enabled design with rigorous experimental validation. ChemPass AI™ ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results